WilmerHale Represents Underwriters in Candel Therapeutics IPO

WilmerHale Represents Underwriters in Candel Therapeutics IPO

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the initial public offering of 9,000,000 shares of common stock of Candel Therapeutics, Inc., for aggregate gross proceeds of $72 million. The offering priced on July 26, 2021 at $8.00 per share and closed on July 29, 2021.

The team representing the underwriters consisted of Partner Lisa Firenze, Counsel Stephanie Leopold, Senior Associate Sean Linnehan and Associates Erin Bruynell and Amanda Navarro, with support from Partners Bruce Manheim and Colleen Superko and Attorney Heidi Treiber.


Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel